Full Breakdown
Evaluating Treatment Outcomes in HIV-1 Patients: A Comparative Study of Antiretroviral Regimens
9/3/2025, 6:00:26 AM
Study Overview and Objectives
This article examines a clinical study aimed at evaluating the effects of two different antiretroviral treatment regimens on body weight and metabolic parameters in HIV-1 infected individuals. Participants were randomized to either switch to a coformulated regimen of Dolutegravir (DTG) and Lamivudine (3TC) or continue with a regimen that included Abacavir (ABC) alongside DTG and 3TC. The primary outcome focused on the change in body weight from baseline to week 48, while secondary outcomes included fat distribution, body composition, and various metabolic and cardiac parameters.
Participant Eligibility and Study Design
Eligible participants were adults aged 18 years or older with HIV-1 infection, having been treated with the DTG/ABC/3TC regimen for at least six months. Exclusion criteria included preexisting resistance to 3TC or DTG, hepatitis B infection, recent cancer, unstable cardiovascular disease, diabetes, pregnancy, or breastfeeding. Participants were recruited from outpatient clinics at Copenhagen University Hospital - Amager and Hvidovre and Rigshospitalet. A total of 70 participants were enrolled, with a randomization ratio of 2:1 favoring the intervention arm.
Data Collection and Analysis
Data were collected at baseline, week 24, and week 48, including assessments of body weight, body composition via dual-energy X-ray absorptiometry (DEXA), and fat distribution through computed tomography (CT). Additionally, liver stiffness and fat infiltration were evaluated using liver elastography. The study employed intention-to-treat (ITT) and modified ITT analyses to assess outcomes, utilizing linear mixed models for repeated measurements and multiple imputation for missing data.
Key Findings
The primary outcome indicated an estimated weight change of 0 to -1 kg for the DTG/3TC arm and +2 kg for the DTG/ABC/3TC arm at 48 weeks. Secondary outcomes revealed differences in fat distribution and metabolic parameters, although specific results were not detailed in the provided sources. Participants were withdrawn from the study in cases of virological failure, defined as a plasma viral load exceeding 50 copies/ml.
Criticism and Opposition
While the study design and outcomes were methodologically sound, potential criticisms could arise regarding the exclusion criteria, which may limit the generalizability of the findings to broader populations. Additionally, the reliance on self-reported adherence and the impact of the radiographer strike on data collection could raise concerns about the robustness of the results.
Official Statements & Responses
The study protocol was reviewed and approved by relevant ethical boards, ensuring compliance with ethical guidelines. The research team emphasized the importance of informed consent and participant safety throughout the study process.
Verbatim Quotes
- “The primary outcome was defined as the difference in change in body weight from baseline to week 48 between the two treatment arms.” — Study Protocol
- “Participants were withdrawn from study participation in cases of virological failure, which was defined as a plasma viral load > 50 copies/ml measured by two consecutive blood samples within 30 days.” — Study Conclusion
What's Next
Further analysis of the secondary outcomes and long-term follow-up of participants will be essential to fully understand the implications of switching antiretroviral regimens on health outcomes in HIV-1 patients. Future studies may also explore the effects of these treatments in diverse populations and settings.
